Passage Bio Inc expected to post a loss of 48 cents a share - Earnings Preview

Passage Bio

31/07/2023 19:31

* Passage Bio Inc  PASG.OQ   PASG.O  is expected to show no
change
in quarterly revenue when it reports  results on August 2
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Passage Bio Inc is
for a
loss of 48 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 7 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Passage Bio
Inc
is $8.5​, above​ its last closing price of $0.88. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.50       -0.50      -0.63     Missed  -27.2
 Dec. 31 2023  -0.51       -0.52      -0.49     Beat    6.3
 Sep. 30 2022  -0.74       -0.79      -0.49     Beat    38​
 Jun. 30 2022  -0.79       -0.83      -0.73     Beat    11.7
 ​​Mar.        -0.91       -0.89      -0.79     Beat    11
 31 2022                                                
 Dec. 31 2021  -0.90       -0.89      -0.95     Missed  -7.2​
 Sep. 30 2021  -0.89       -0.86      -0.87     Missed  -1
 Jun. 30 2021  -0.76       -0.76      -0.90     Missed  -18.9
 This summary was machine generated July 31 at 18:31 GMT.  All
figures in US dollars  unless otherwise stated